Cytophage Technologies (TSXV:CYTO) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Debt-to-Equity?

Cytophage Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Cytophage Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Cytophage Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$5.41 Mil. Cytophage Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cytophage Technologies's Debt-to-Equity or its related term are showing as below:

TSXV:CYTO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.04 Max: 0.05
Current: 0.01

During the past 3 years, the highest Debt-to-Equity Ratio of Cytophage Technologies was 0.05. The lowest was 0.03. And the median was 0.04.

TSXV:CYTO's Debt-to-Equity is ranked better than
99.91% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSXV:CYTO: 0.01

Cytophage Technologies Debt-to-Equity Historical Data

The historical data trend for Cytophage Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Debt-to-Equity Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

0.05

0.03

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Debt-to-Equity	0.05	N/A	0.03	0.03	-

Competitive Comparison of Cytophage Technologies's Debt-to-Equity

For the Biotechnology subindustry, Cytophage Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Debt-to-Equity falls into.

Cytophage Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cytophage Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	5.411
	=	0.00

Cytophage Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	5.411
	=	0.00

Cytophage Technologies (TSXV:CYTO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cytophage Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.